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70 Poster Session Iinduction/consolidation treatment (n5 3) or as a salvage therapy af-
ter failing multiple prior therapies including autologous SCT (n 5
9). Median number of prior therapy was 4 (range, 2–7). Condition-
ing regimen consisted of fludarabine (180 mg/kg), busulfan (8 mg/
kg), and anti thymocyte globulin. Graft-vs-host disease (GVHD)
prophylaxis consisted of tacrolimus alone.
Results: Median age was 54 years with 50% males. Four patients
had matched unrelated donor (MUD) SCT and 8 had matched sib-
ling SCT. Median CD341 cell dose was 7  106/Kg ideal body
weight. All patients engrafted (with 100% donor chimerism) except
for one patient who died on day 19 due to severe fludarabine neu-
rotoxicity. Three patients never achieved zero absolute granulocyte
count (AGC) and 4 patients did not require platelet transfusions.
Time to AGC . 500 was 18.5 days (n 5 10), and to platelet .
20,000/ul was 12 days (n 5 7). TRM was seen in 3/12 patients
(25%), while 7 patients died of disease progression. The incidence
of grade II-IV acute and extensive chronic GVHD was 45% for
both. Post SCT donor lymphocyte infusions (2–4 infusions) were
used in conjunction with salvage therapy to treat persistent or re-
lapsed MM in 3 patients, all died of progressive disease. Overall re-
sponse rate was 55% with 6 of 11 patients achieving partial
remission or better, and only two patients achieving complete re-
mission. Median progression free and overall survival was 10 and
21.5 months. Currently, 3 patients are alive 31–75 months since
transplant, two of them after MUD SCT, one in complete remis-
sion and the other two with stable residual disease. One patient
never had prior autologous SCT. All three patients have been
treated for mild to moderate extensive chronic GVHD, but no
MM therapy. In conclusion, our results indicate that NMA alloge-
neic SCT is an effective salvage therapy in 25% of patients with ad-
vanced MM, however relapse remains the main reason for failure.PEDIATRIC DISORDERS190
THE EFFECT OF OVERWEIGHT ANDOBESITY ON INTRAVENOUS (IV) BU-
SULFAN METABOLISM IN CHILDREN UNDERGOING REDUCED INTEN-
SITY CONDITIONING (RIC) FOR ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION (AHSCT)
Browning, B., Thormann, K., Coyne, K., Kletzel, M. Children’s Memo-
rial Hospital, Chicago, IL.
Pediatric obesity is growing problem in the US. According to the
Centers for Disease Control and Prevention (CDC), 16% of chil-
dren between the ages of 6–19 are considered overweight or obese
with an additional 15% of the pediatric population considered at
risk for becoming overweight. The purpose of this study was to in-
vestigate the predicted versus actual AUC of IV busulfan in children
who are overweight or obese to determine if increased body weight
and adiposity affects the metabolism of this drug.
Retrospective data was collected on 52 pediatric HSCT patients
from 2000–2007 at Children’s Memorial Hospital who underwent
RIC with fludarabine 25 mg/m2/day  5 days and busulfan (single
daily dose) dose adjusted by a test dose  2 days 1/- ATG. Test
dose (TD) of 0.8 mg/kg was given over 2 hrs 5–10 days prior to
stem cell infusion and pharmacokinetic (PK) blood draws were
taken at 4 time points (end of infusion, 30 min., 2, 4 hours post in-
fusion). Regimen doses (RD) were calculated from the AUC and
clearance of the TD and were initiated 5–4 days prior to stem cell
infusion. PK data was collected at 5 time points for the RD (end
of the infusion, 30 min., 2, 5, 24 hours post infusion). All samples
were sent to Seattle Cancer Care Alliance Clinical Pharmacokinet-
ics Laboratory for analysis and calculation of AUC and clearance.
Retrospective data collected included demographics, diagnosis, ht,
wt, calculated BMI, concomitant meds, liver function tests
(LFT’s), TD and RD AUCmMol*min, clearance ml/min/kg and
the dose of BU mg/kg given. Subject were graphed on standard
CDC body mass index (BMI) growth charts then stratified into
BMI categories: \25th%tile, 25–75th%tile, 85–95th%tile and
.95th%tile.
37% of the subjects were overweight or obese. 61% of the sub-
jects reached the targeted AUC with the TD; 80% of the subjects
reached the targeted AUC with the RD. Modifications were madeto the RD in 42 pts. No statistical significance was found between
BMI and TD AUC (p 5 0.31) or RD AUC (p 5 0.96). There was
also no statistical correlation between obtaining targeted TD or
RD AUC and age, sex, LFT’s, concomitant medications, source
of stem cells, diagnosis or weight. It was observed that more TD
and RD AUC anomalies occurred in children who were overweight
or obese. See table. Based on this data, no changes should be made
in current dosing for children who are overweight or obese if the
RD is based on a TD, however, more research with a larger sample
size is warranted.
AUC Trends in each BMI Category
85–95th%tile .95th%tileBMI \25th%tile 25–75th%tile (overweight) (obese)Total Number of Children in
Each Category14 19 9 1027% 37% 17% 19%Test Dose and Regimen Dose
CombinedTotal # of TD or RD AUC’s
\800 and .1200 or\3200 or
.4800 (lower or higher than
predicted)5 9 4 736% 47% 44% 70%Total # of low TD or RD
AUC’s\800 or\3200 (lower
than predicted)5 5 1 136% 26% 11% 10%Total # of high TD and RD
AUC’s .1200 or .4800
(higher than predicted)0 4 3 60% 21% 33% 60%Test DoseTotal # of low TDAUC’s
\800 (lower than predicted)
2 4 0 114% 21% 0% 10%Total # of high TD AUC’s
.1200 (higher than predicted)0 2 3 30% 11% 33% 30%Regimen DoseTotal # of low RD ACU’s
\3200 (lower than predicted)
3 1 1 021% 5% 11% 0%Total # of high RD ACU’s
.4800 (higher than predicted)0 2 0 30% 11% 0% 30%191
ATYPICAL TERATOID/RHABDOID TUMORS: IMPROVED OUTCOME WITH
HIGH-DOSE CHEMOTHERAPY
Schechter, T., Gassas, A., Bartels, U., Doyle, J., Bouffet, E. The Hospital
for Sick Children, Toronto, ON, Canada.
Background: Atypical teratoid/Rhabdoid tumors (ATRT) of the
brain are highly malignant central nervous system (CNS) tumors
which carry a grave prognosis. It comprises up to 15% of malignant
brain tumors. Current treatment recommendations include maxi-
mal surgical resection followed by chemotherapy, with or without
radiation. Despite intensive therapy, the prognosis is poor and the
reported median survival range between 8–17 months; children
younger than 3-yrs of age carry an even worse prognosis. High
dose chemotherapy (HDC) with autologous hematopoietic stem
cell transplant (AHSCT) has been proposed in order to improve
survival. Patients and Methods: A cohort of consecutive children
with ATRT at the Hospital for Sick Children, Toronto, (2000 to
2006). Treatment recommendation during that period was maxi-
mum surgical resection, intensive chemotherapy followed by 3
courses of sequential HDC (with thiotepa and carboplatin) with
AHSCT. Radiation treatment and adjuvant therapy were discussed
case by case. Results: Eight children with ATRT were evaluated in
the study period; 3 patients younger than 1 year with disseminated
disease were not treated. Five patients were treated (demographics,
tumor characteristics, treatment and outcome summarized in the ta-
ble). A total of 15 courses of HDC and AHSCT were performed in 5
patients. There was no treatment related mortality (TRM) follow-
ing HDC; 3 children had febrile neutropenia. Blood cultures in
all episodes were negative. One patient required admission to inten-
sive care unit for a short period. All patients developed mucositis
and were treated with morphine. Engraftment occurred at a mean
Poster Session I 7110.6 days. Conclusions: Despite known dismal prognosis, 3 out of
the 5 patients treated in our center are well at a follow-up of more
than 2 years. One of these survivors is an infant with metastatic
ATRT. There was no TRM or severe morbidity. This approach
with HDC and AHSCT needs to be validated in larger studies.
ATRT patients’characteristics
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otal resection.
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and outcome1 43,M Frontal lobe No GTR No No 38, alive2 11, F Posterior fossa Yes GTR No Tamoxifen 24, alive3 31, F Posterior fossa No GTR Yes-focal No 26, alive4 40,M Cerebello-pontine
angleNo STR Yes-focal No relapse-16, died5 39,F Frontal lobe Yes STR No Tamixifen relapse-8, died192
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INBORN ERRORS
IN METABOLISM; A NATIONAL SURVEY IN JAPAN
Takakura, H.1, Shimizu, T.1, Tanaka, A.2, Okuyama, T.3, Kato, K.4,
Ohashi, T.5, Sakai, N.6, Mugishima, H.7, Suzuki, Y.8, Kato, S.1. 1Tokai
University School of Medicine, Isehara, Kanagawa, Japan; 2Osaka City
University, Osaka, Japan; 3National Center for Child Health and Devel-
opment, Tokyo, Japan; 4 Japanese Red Cross 1st NagoyaHospital, Nagoya,
Aichi, Japan; 5 Jikei Medical College, Tokyo, Japan; 6Osaka University
School of Medicine, Osaka, Japan; 7Nihon University School of Medicine,
Tokyo, Japan; 8Gifu University School of Medicine, Gifu, Japan.
Purpose: Hematopoietic stem cell transplantation (HSCT) has
been successfully applied to some forms of inborn errors in metab-
olism (IEM). However, its long term effects have varied according
to the type and the stage of disease. Among mucopolysaccharidosis
(MPS), the efficacy of HSCT in type II (Hunter’s disease) has been
controversial.
A nationwide survey was performed to collect data on transplant
outcomes and long term clinical effects in HSCT for IEM in Japan,
in order to clarify the problems and the efficacies in those diseases. A
special focus was put on Hunter’s disease, the most common form
among Asian MPS patients, and a detailed comparison was made
with patients to whom HSCT had not been applied. Patients:
Data were collected on 141 patients from 35 institutes. HSCT
were done during the period between 1985 and 2004, and the min-
imum follow-up was one year in long term survivors.
Diseases: MPS 72, adrenoleucodystrophy (ALD);38, I-cell dis-
ease;6, metachromatic leucokystrophy (MLD);7, others;14
Sex: M/F 113/28
Age at first HSCT:median 4 years old (0–15)
Donors (1st HSCT): siblings;63, parents;11, unrelated;67
HLA compatibility (1st HSCT): match;108, mismatch;32, un-
known;1
Cell sources (1st HSCT): BM;113, PB;2, CB;22 Transplant
Outcomes: Survival: alive;114 (81%), dead;27(19%)
Overall survival (OS) rates according to disease: MPS(N 5
71);87%, ALD(N 5 38);76%, Gaucher(N 5 4);75%, MLD(N 5
7);43%, I-cell(N 5 6);22%. (P 5 0.006)
OS according to donor: sibling(N 5 62);87%, UBM(N 5
48);80%, UCB(N 5 19);68%, parents(N 5 11);64%. (P 5 0.002)
OS according to HLA compatibility: match(N5 108);79%, mis-
match(N 5 32);69%. (P 5 0.008)
OS according to cell source: BM(N 5 117);79%, CB(N 5
22);58%. (P\ 0.001) Clinical Effects: Long term clinical effects
varied from disease to disease and from patient to patient. Patients
who were transplanted in early stages have benefited more than pa-
tients transplanted in advanced stages.
A comparison in Hunter’s disease between 44 transplanted pa-
tients and with untransplanted patients revealed that quality of life
improved rapidly following HSCT due to normalization in range
of joint movement, and that neurological progress could be pre-vented to some extent even in severe form. Conclusion: Our study
confirmed the efficacy of HSCT in selected patients with IEM in
early stages. A detailed comparison in Hunter’s disease with un-
transplanted patients suggested the efficacy of HSCT even in severe
form, but the neurological effect seemed to be less than that in
Hurler’s disease (MPS IH).193
OSTEONECROSIS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
Vrooman, L., Duncan, C., Eaton, M., Silverman, L.B., Lehmann, L.
Dana-Farber Cancer Institute, Boston, MA.
Background: Osteonecrosis (ON) is a potentially devastating
complication of pediatric hematopoietic stem cell transplantation
(HSCT). We report the frequency of symptomatic ON in pediatric
patients (pts) who underwent allogeneic HSCT at Children’s Hos-
pital Boston/Dana-Farber Cancer Institute over a 6-year period.
Methods: We retrospectively reviewed the medical records of
293 consecutive pts who underwent 307 allogeneic HSCTs between
January 1, 2000 and December 31, 2006. Diagnosis of ON was
based on patient symptoms and confirmed by review of the attend-
ing radiologist’s final reading of at least one radiographic study.Re-
sults: A total of 15 pts (5.1%) developed symptomatic ON.
Underlying diagnoses included 5 pts with acute lymphoblastic lym-
phoma (ALL), 3 acute myeloid leukemia, 1 myelodysplastic syn-
drome, 3 chronic myeloid leukemia, 2 aplastic anemia, and 1
sickle cell disease. Eleven pts underwent unrelated donor HSCT
and 4 had matched sibling transplants. Eleven pts (73%) were
$10 years of age at the time of HSCT. Thirteen (87%) developed
chronic graft-versus-host disease (GVHD), 9 of whom received ste-
roids for over 12 months. The 2 pts without chronic GVHD had an
underlying diagnosis of ALL. Two pts underwent a second alloge-
neic HSCT for relapsed disease and developed ON only after the
second transplant. One pt was diagnosed w/ON prior to HSCT
with ON that worsened significantly post HSCT. With regard to
sites of ON, only 2 pts had a single site (unilateral hip and unilateral
knee). Six pts developed bilateral ON of the hips. Of these, 2 pts also
had bilateral knee ON (one also with ON of the sacrum). Five ad-
ditional pts developed bilateral ON of the knees and 2 pts developed
bilateral ON of the ankles. Two pts underwent surgical interven-
tions; 1 pt underwent core decompression for bilateral knee ON,
and the other, arthroscopy with debridement and drilling of the ta-
lus for extensive ankle involvement. Eight of the 15 pts are currently
surviving. Four pts are known to have persistent complaints of joint
pain. Conclusion: Symptomatic ON developed in 5.1% of pts who
underwent allogeneic HSCT. The majority of pts with ON were af-
fected at multiple sites. Further interventional and follow-up studies
aimed at identifying those at greatest risk, preventing the complica-
tion, and decreasing morbidity from ON are needed in the pediatric
HSCT population.194
INTRAVENOUS BUSULFAN IN CHILDREN PRIOR TO HAEMATOLOGICAL
STEM CELL TRANSPLANTATION, HOW NARROW IS THE THERAPEUTIC
WINDOW?
Bartelink, I.H.1, Bredius, R.G.M.2, Egberts, T.C.G.1, Suttorp, M.M.2,
Bierings, M.1, Knibbe, C.3,4, Zwaveling, J.2, Boelens, J.J.1. 1UMCU,
Utrecht, Netherlands; 2LUMC, Leiden, Netherlands; 3Antonius Hospi-
tal, Nieuwegein, Netherlands; 4Leiden/Amsterdan Center for Drug Re-
search, Leiden University, Leiden, Netherlands.
Background: A high dose of busulfan (BU) combined with ther-
apeutic drug monitoring as been suggested to be associated with
higher event free survival (EFS) rates due to less graft-failure/re-
lapses and lower toxicity. Since 2001 we (LUMC and UMCU)
are using intravenous BU in various myelo-ablative regimen: we
have targeted to various area’s under the curve (AUC) and have
given BU either once daily or 4 times a day. In this study we retro-
spectively analysed the association between busulfan exposure
